Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus (Q38069508)

28 August 2017

1 reference

title

Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus (English)

1 reference

28 August 2017

1 reference

Kaapjoo Park

1

1 reference

28 August 2017

publication date

1 December 2012

1 reference

Archives of Pharmacal Research

28 August 2017

published in

1 reference

28 August 2017

volume

35

1 reference

28 August 2017

issue

12

1 reference

28 August 2017

page(s)

2029-2033

1 reference

Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Allosteric activators of glucokinase: potential role in diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Glucose-induced conformational changes in glucokinase mediate allosteric regulation: transient kinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Metabolic activation of N-thiazol-2-yl benzamide as glucokinase activators: Impacts of glutathione trapping on covalent binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Liver glucokinase: An overview on the regulatory mechanisms of its activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Assessing the potential of glucokinase activators in diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

2,3-Disubstituted acrylamides as potent glucokinase activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-012-1201-9

10.1007/S12272-012-1201-9

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1039035438

0 references

1 reference